C irrhosis affects 633,000 Americans, or 0.27% of the US population, 1 and often is characterized by an unpredictable and rapid clinical deterioration leading to death. 2 Liver transplantation is the only effective cure for decompensated cirrhosis. However, organ shortages restrict availability to only 5500 patients receiving this procedure annually for all forms of liver disease, compared with the 36,400 deaths from decompensated cirrhosis each year.
3, 4 As a result, patients with cirrhosis who have an estimated 6-month life expectancy experience significant suffering and generate greater caregiver burden at the end of life compared with patients dying of other chronic conditions. 5 Despite increased attention paid to improving endof-life care for patients with liver disease, 6, 7 little is known about the current quality of care, resources, and costs associated with treating these patients. A study using the Health and Retirement Survey found that patients with cirrhosis report worse health status and require more caregiver support compared with age-matched patients without cirrhosis, but the sample was limited to Medicare recipients and hospital illness experiences and costs were not detailed. 8 For hospitalized patients, palliative care consultation has been shown to be associated with improved patient satisfaction, increased provider satisfaction, and lower intensive care unit utilization, making it a marker for better inpatient end-of-life care quality. 9, 10 In 2014, an observational study from an academic medical center in Canada showed that nontransplant candidates with cirrhosis had a mean survival of 52 days after being removed from the liver transplant list. For those hospitalized, receipt of inpatient palliative care consultation was as low as 11%, whereas 48% experienced intensive care unit admission and 17% initiated hemodialysis. 11 Use of treatments and costs during terminal hospitalizations for patients with decompensated cirrhosis have not been characterized in the United States. We used national data to describe palliative care consultation and resource utilization for patients with decompensated cirrhosis during terminal hospitalizations. Our hypothesis is that the overall rate of palliative care consultation in our population would be low while utilization in the form of procedures and total costs would be high.
Methods

Data Set
The National Inpatient Sample (NIS) is a large national database that contains annual clinical and resource utilization information from hospitalizations across the United States. It is a product of the Healthcare Cost and Utilization Project (HCUP) and the Agency for Healthcare Research and Quality. 12 National data are obtained from a total of 44 states, and each state database contains random samples of hospitalizations from HCUP member hospitals, stratified by census division, hospital ownership, setting, teaching status, and bed size as classified by the American Hospital Association Annual Survey of Hospitals. In 2012, the database began to exclude hospitalizations from rehabilitation centers and long-term acute care hospitals.
Patient Cohort
Our population of interest was patients 18 years and older who died during their hospitalization and stayed in the hospital for at least 3 days. 13 Patients were identified as having end-stage liver disease by using validated International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes for end-stage liver disease (Supplementary Table 1 ). Codes for identifying cirrhosis and liver decompensation were associated with a positive predictive value of 88% and 91%, respectively.
14,15
Variables of Interest
The main outcomes of interest in our study were the proportion of patients with decompensated liver disease receiving palliative care consultation during the terminal hospitalization and the total cost of the terminal hospitalization. Receipt of palliative care consultation was identified by the presence of ICD-9-CM code V66.7, among listed subject diagnosis codes, consistent with previous studies. 16, 17 We calculated the total hospital cost of each hospitalization by applying hospital-specific and group average all-payer inpatient cost-to-charge ratios from the Center for Medicare and Medicaid Services provided by HCUP to the reported hospital charges. Costs then were adjusted for inflation using the Consumer Price Index and expressed as 2013 dollars. 18 In addition, we included several patient-level and hospital-level factors using a prespecified conceptual model. Patient-level data included year of hospitalization, demographics, Charlson comorbidity index, 19 reason for admission, length of stay, presence of hepatocellular carcinoma (HCC), transplant status (defined as patients listed for or receiving transplant during hospitalization), and frequency of invasive procedures. Hospital-level variables were hospital bed size, hospital location/teaching status, hospital ownership, and hospital region. The ICD-9-CM codes used for analysis are described in Supplementary Table 1.
Statistical Analysis
We applied survey weights and adjustments from the NIS to provide national population estimates and to account for the changes in sampling in 2012. Bivariate analyses were performed examining differences in patient characteristics, cost, length of stay, and procedure burden based on receipt of palliative care using weighted regression and weighted Pearson-Chi-squared tests. Then, multivariate regression analyses were performed to determine factors associated with palliative care and factors associated with total cost. To minimize bias from missing values, we used multiple imputation by chained equations 20 for race (7.7% missing), insurance status (0.3% missing), average household income (3.3%), and all hospital factors (1.2% missing). Of the final sample, 645 patients lacked cost data and were excluded from the multivariate analysis involving predictors of cost but were included in the analysis involving predictors of palliative care. Sensitivity analyses were conducted examining the relationship between palliative care consult and costs in 2 alternative settings: excluding transplant candidates and recipients, and adjusting for treatment selection using doubly robust inverse probability of treatment weighted analysis. 21 Differences with P values less than .05 were considered statistically significant. All analyses were performed with STATA 14.0 software (STATA Corp, College Station, TX).
Results
Descriptive Statistics
From 2009 to 2013, the NIS contained 38,051,324 hospital discharges, representing 189,116,625 discharges. Among the 449,157 terminal hospitalizations over the 5-year period for adults with a length of stay of at least 3 days, 12,380 (2.8%) hospitalizations were for patients with end-stage liver disease. When weighted, our total sample size was 59,703 patients. Because these hospitalizations were terminal, each discharge represented a unique patient.
Among patients dying in the hospital with decompensated liver disease from 2009 to 2013, 30.3% received a palliative care consultation during the hospitalization. Palliative care consultation increased annually (18.0% to 36.6% from 2009 to 2013; P < .05). The inpatient decedent population with decompensated liver disease was mostly male (weighted, 62.6%), Caucasian (weighted, 65.9%), and hospitalized at large (weighted, 69.6%), urban/teaching (weighted, 61.9%), and private nonprofit hospitals (weighted, 71.7%). Forty-one percent were covered by Medicare. Septicemia was the most common identified reason for admission in 24.0% of patients. Of the decedents, 7.4% carried a diagnosis of HCC, 1.5% were listed for liver transplant, and 0.8% received transplant ( Table 1) .
The mean cost for the terminal hospitalization was $48,551 (SE: $1142), which did not significantly change from $47,969 in 2009 to $48,956 in 2013 (P ¼ .77). The median length of stay was 10 days (interquartile range, 6-17 days). Twenty-three percent of patients received an endoscopy and 43% of patients received a paracentesis. Fifty-six percent of patients received mechanical ventilation and 43% received a blood transfusion. Dialysis was initiated for 16.2% of patients and parenteral nutrition was used 13.1% of the time. Cardiopulmonary resuscitation was attempted in 6.2% of these patients before death (Table 2) .
Factors Associated With Palliative Care Consultation
Bivariate analyses showed significant differences between decedents receiving and not receiving palliative care with respect to race, annual household income, Charlson comorbidity index, presence of HCC, and hospital factors. Reasons for admission were not significantly different between these groups ( Table 1 ). The mean total costs, length of stay, and procedure burden all were significantly lower for patients who received palliative care consultation (Table 2) .
Controlling for all other factors, patients with end-stage liver disease were increasingly likely to receive a palliative (Table 3) . Palliative care receipt also was stratified by hospital bed size and hospital teaching status. Palliative care rates are highest at large urban teaching hospitals (33.0%), and lower at small rural (19.5%) and small urban nonteaching hospitals (22.4%). However, rates of palliative care appear to be increasing at nearly every type and size of hospital over time. At large hospitals, patients with HCC appear to receive more palliative care consultation than patients without HCC. At large urban/teaching hospitals, African Americans and Hispanics have lower odds of receiving palliative care whereas Native Americans have higher odds compared with Caucasians (Supplementary Table 2 ).
Factors Associated With Hospital Cost
In the model predicting the total cost of the terminal hospitalization, palliative care consultation was associated with lower overall costs when adjusting for all other covariates (-$10,062; 95% CI, -$12,726 to -7399). Having been listed or receiving liver transplant during the hospitalization was associated with higher overall costs compared with unlisted status ($92,397; 95% CI, 69,331-115,463). Patients receiving hospital charity care or receiving other forms of government assistance were associated with lower costs compared with Medicare recipients. Increasing age, comorbidity, and diagnosis of HCC were associated with lower costs, whereas higher household income status was associated with higher costs. Hospital factors also significantly contributed to cost variation. Patients hospitalized at facilities with more beds, government ownership, urban location with teaching status, and Midwest and West coast regions tended to incur higher costs. Finally, adjusting for all these predictors, year of hospitalization was not associated significantly with cost (Table 4) .
Sensitivity Analysis
In a sample excluding transplant candidates and recipients, palliative care still was associated with lower costs (-$9010; 95% CI, -11,491 to -6527). Doubly robust inverse probability of treatment weighted analysis also showed that the mean average treatment effect of palliative care consultation on cost was -$10,746, adjusting for confounding related to treatment selection from observed variables (Supplementary Table 3 ).
Discussion
Among decedents with end-stage liver disease, we found that utilization of palliative care consultation during terminal hospitalizations was low but increased from 2009 to 2013. Total costs of hospitalization for end-stage liver disease patients did not increase significantly. Adjusting for patient and hospital factors, this national observational study showed that palliative care consultation is associated with lower costs of terminal hospitalization.
Recognizing that this is a decedent population, the proportion of patients receiving palliative care consultation-30%-was low. However, this estimate was higher than 11%, which was reported from the single-center Canadian study investigating mortality in nontransplant candidates. 11 The small proportion of these decedents receiving palliative care is particularly important given the high level of treatment intensity received before death. Comparing our decompensated liver disease decedents from 2009 to 2013 with an in-hospital decedent group previously analyzed by HCUP in 2007, length of stay (10 vs 8.8 d) and utilization of aggressive treatment was considerably higher in our end-stage liver disease sample, including mechanical ventilation (56.1% vs 24.8%), hemodialysis (16.2% vs 1.2%), and blood transfusion (43.4% vs 3.8%). 22 Our bivariate analyses showed that palliative care consultation was associated with a reduced hospital length of stay and a reduction in nearly all procedures.
Oncology guidelines have long recommended involvement of palliative care at the time of diagnosis of advanced disease in patients with malignancies, 23 and although palliative care and hospice referral rates in noncancer conditions still remain low, 24-26 specialty societies treating heart failure, chronic kidney disease, and respiratory disorders recently published guidelines that endorse involvement of palliative care in management of these chronic conditions. [27] [28] [29] A few small studies have explored methods for integrating palliative care earlier in the care of patients with end-stage liver disease [30] [31] [32] ; however, guidelines regarding when to consider palliative care are needed. Our finding that transplantation listing or receipt is associated with lower odds of receiving inpatient palliative care mirrors findings from a previous study showing an association between liver transplantation status and poorer end-of-life care quality. 33 Evaluating palliative care needs at the time of liver transplant referral may be needed to facilitate access to high-quality end-of-life care for patients who may not survive before, during, or immediately after surgery. We also observed that racial and ethnic minorities tend to receive less palliative care consultation than whites, which is consistent with previous literature. 34 Racial and ethnic disparities in access to palliative care in liver disease presents an important area for future research. Finally, our finding that patients at larger hospitals tend to receive more palliative care is consistent with a study that found that 97% of hospitals with more than 300 beds have palliative care consultation services compared with only 67% of hospitals with more than 50 beds. 35 Our stratified analysis, however, showed that rates of palliative care consultation for these patients have been increasing at nearly all types and sizes of hospitals over time.
The overall cost of end-of-life care for patients with endstage liver disease is high, with an estimated cost per terminal hospitalization of $48,551 over the 5 years studied. This compares with a mean cost of terminal hospitalization estimated at $23,017 using HCUP data from 2007. 22 Our study had several strengths. First, although several reports have called for greater involvement of palliative care in the management of end-stage liver disease, this study highlights low palliative care rates as well as high utilization in the form of costs, length of stay, and procedure burden during terminal hospitalizations for these patients. Second, NIS is a large and comprehensive data set that accurately reflects the diverse patient population and hospital settings in the United States. The gender and racial composition seen in our data, for instance, is similar to 2014 Vital Statistics data from the Centers for Disease Control and Prevention. 4 Finally, our study showed that palliative care consultation was associated with lower overall costs when controlling for demographics and hospital characteristics. A multicenter randomized control study found that inpatient palliative care consultation was associated with $4855 cost savings over 6 months for patients with life-limiting illnesses. 9 Our study found an average of $10,062 in reduction in total costs per patient associated with palliative care consultation in decedents. This value did not change significantly when excluding transplant patients and may, in fact, be an underestimation of its true effect based on our sensitivity analysis. This supports that integration of palliative care in this population has the potential for cost savings.
Despite these strengths, there were some notable limitations. As mentioned, metrics for palliative care consultation and liver transplantation using ICD-9-CM codes have not been validated. In addition, although palliative care is associated with lower overall hospital costs in this study, given the observational nature of the study, there likely are unmeasured variables not captured in the data set that may confound this relationship. Next, although palliative care and lower costs both have been associated with improved end-of-life quality, [36] [37] [38] specific outcome measures, including timely symptom management and provision of psychosocial and caregiver support, were not captured. The presence of palliative care consultation and lower costs do not guarantee high-quality, end-of-life care, and, similarly, the absence of palliative care consultation or higher costs do not mean that end-of-life care quality metrics are not achieved. For instance, patients who died shortly after admission may have received appropriate end-of-life care without consultation and patients experiencing long hospitalizations with high total costs still may receive high-quality, end-of-life care. The NIS also is limited in its ability to measure other key variables, including timing of palliative care consultation, availability of inpatient palliative care services at HCUP member hospitals, and prior health care encounters. Finally, although all hospitalizations were terminal, it is not fully clear whether causes of death were liver-related or owing to other external factors leading to death such as a motor vehicle accident, suicide, or homicide. Given the advanced stage of liver disease, however, we believe other causes are likely rare.
Conclusions
Our study corroborates previous data suggesting that rates of palliative care consultation in patients with end-stage liver disease are low, while also showing that costs are exceedingly high for these terminally ill patients. Our findings of racial and ethnic disparities in palliative care access and variations in palliative care access and cost based on hospital factors and transplant status present unique opportunities for research and quality improvement for this population. The association of palliative consultation with lower costs and procedure burden at the end of life suggests that improved palliative care in this population may be an opportunity for improved quality, efficiency, and value for patients with end-stage liver disease.
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